atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that pharmacodynamic data on GRX-917, a deuterated version of etifoxine, was selected for poster presentation and presented yesterday at the Society for Biological Psychiatry (SOBP) Annual Meeting. The SOBP annual meeting is being held in San Diego from April 27–29.

Late Breaking Poster Presentation Details:

Title: Pharmacodynamic Profile of GRX-917 Using Quantitative EEG in a Phase 1 Study

Poster Number: T46

Session Title: Poster Session I

Session Date & Time: Thursday, April 27th 5:30pm – 7:30pm PT

The analyses in the poster presentation are focused on the pharmacodynamic profile of GRX-917 and are based on the biomarker data from the completed Phase 1 study. As measured by EEG, GRX-917 demonstrated a statistically significant increase in beta power, a marker of potential anxiolytic effects, and which is similar to what is seen with exogenous neurosteroids and benzodiazepines. Unlike benzodiazepines, however, GRX-917 was found to not reduce alpha power, the decrease of which is associated with potential sedative effects. In the Phase 1 study, GRX-917 was safe and well-tolerated, with sedation comparable to placebo and consistent with the EEG results on alpha power.

The poster will be made available on the atai Life Sciences website at

About atai Life Sciences

atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.

By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies to achieve clinically meaningful and sustained behavioral change in mental health patients.

atai’s vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilled life.